Controversies in the Evaluation and Management of Atypical Melanocytic Proliferations in Children, Adolescents, and Young Adults

Restricted access

The rising incidence of melanoma in children has brought increased attention to the clinical and pathologic diagnosis of pigmented lesions in the pediatric age group. Although melanoma in infancy and early childhood is often associated with large congenital nevi, in older children and teenagers it is most often sporadic, occurring in patients with a low skin phototype and substantial sun exposure. The rarity of this potentially fatal disorder demands astute clinical attention and a high index of suspicion for atypical lesions in pediatric patients. The challenges include the difficult decision of whether to biopsy and an often equivocal pathologic diagnosis. These diagnostically challenging and equivocal lesions lead to a degree of uncertainty regarding additional workup, prognosis, potential therapy, and follow-up plans. Consultation with a specialty dermatopathologist can be very helpful, and advanced molecular diagnostic techniques may be used in selected circumstances. Although still controversial, good evidence exists to justify a role for sentinel lymph node biopsy. Patients with atypical melanocytic proliferations have a high rate of positive sentinel lymph nodes; however, their outcomes are clearly better than in similarly staged adults with conventional melanoma. With the multiple variables involved and the relative lack of prospectively derived evidence, clinical decision-making is challenging and patients and families may experience considerable stress. This article provides data and weighs the pros and cons of a rationale for decision-making in pediatric and young adult patients with diagnostically challenging melanocytic lesions.

Correspondence: Damon Reed, MD, Sarcoma Department, Moffitt Cancer Center, 12902 Magnolia Drive, FOB 1, Tampa, FL 33612. E-mail: Damon.Reed@moffitt.org
  • 1

    Lewis KG. Trends in pediatric melanoma mortality in the United States, 1968 through 2004. Dermatol Surg 2008;34:152-159.

  • 2

    Wong JR, Harris JK, Rodriguez-Galindo C, Johnson KJ. Incidence of childhood and adolescent melanoma in the United States: 1973-2009. Pediatrics 2013;131:846-854.

    • Search Google Scholar
    • Export Citation
  • 3

    Chao MM, Schwartz JL, Wechsler DS. High-risk surgically resected pediatric melanoma and adjuvant interferon therapy. Pediatr Blood Cancer 2005;44:441-448.

    • Search Google Scholar
    • Export Citation
  • 4

    Moscarella E, Zalaudek I, Cerroni L. Excised melanocytic lesions in children and adolescents: a ten-year survey. Br J Dermatol 2012;167:368-373.

    • Search Google Scholar
    • Export Citation
  • 5

    Ceballos PI, Ruiz-Maldonado R, Mihm MC Jr. Melanoma in children. N Engl J Med 1995;332:656-662.

  • 6

    Hodi FS, O'Day SJ, McDermott DF. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.

  • 7

    Sosman JA, Kim KB, Schuchter L. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-714.

  • 8

    Tom WL, Hsu JW, Eichenfield LF, Friedlander SF. Pediatric “STUMP” lesions: evaluation and management of difficult atypical Spitzoid lesions in children. J Am Acad Dermatol 2011;64:559-572.

    • Search Google Scholar
    • Export Citation
  • 9

    Elder DE, Xu X. The approach to the patient with a difficult melanocytic lesion. Pathology 2004;36:428-434.

  • 10

    Ludgate MW, Fullen DR, Lee J. The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution. Cancer 2009;115:631-641.

    • Search Google Scholar
    • Export Citation
  • 11

    Mills OL, Marzban S, Zager JS. Sentinel node biopsy in atypical melanocytic neoplasms in childhood: a single institution experience in 24 patients. J Cutan Pathol 2012;39:331-336.

    • Search Google Scholar
    • Export Citation
  • 12

    Barnhill RL, Argenyi ZB, From L. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol 1999;30:513-520.

    • Search Google Scholar
    • Export Citation
  • 13

    Cerroni L, Barnhill R, Elder D. Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am J Surg Pathol 2010;34:314-326.

    • Search Google Scholar
    • Export Citation
  • 14

    Trozak DJ, Rowland WD, Hu F. Metastatic malignant melanoma in prepubertal children. Pediatrics 1975;55:191-204.

  • 15

    Lange JR, Palis BE, Chang DC. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol 2007;25:1363-1368.

    • Search Google Scholar
    • Export Citation
  • 16

    Mills O, Messina JL. Pediatric melanoma: a review. Cancer Control 2009;16:225-233.

  • 17

    Ruiz-Maldonado R, Tamayo L, Laterza AM, Duran C. Giant pigmented nevi: clinical, histopathologic, and therapeutic considerations. J Pediatr 1992;120:906-911.

    • Search Google Scholar
    • Export Citation
  • 18

    Paradela S, Fonseca E, Prieto VG. Melanoma in children. Arch Pathol Lab Med 2011;135:307-316.

  • 19

    Berg P, Wennberg AM, Tuominen R. Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma. Melanoma Res 2004;14:251-255.

  • 20

    Bradford PT, Goldstein AM, Tamura D. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J Med Genet 2011;48:168-176.

    • Search Google Scholar
    • Export Citation
  • 21

    Ferrari A, Bono A, Baldi M. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics 2005;115:649-654.

    • Search Google Scholar
    • Export Citation
  • 22

    Bichakjian CK, Halpern AC, Johnson TM. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol 2011;65:1032-1047.

    • Search Google Scholar
    • Export Citation
  • 23

    Coit DG, Andtbacka R, Anker CJ. Melanoma. J Natl Compr Canc Netw 2012;10:366-400.

  • 24

    Wood J, Butler CC, Hood K. Antibiotic prescribing for adults with acute cough/lower respiratory tract infection: congruence with guidelines. Eur Respir J 2011;38:112-118.

    • Search Google Scholar
    • Export Citation
  • 25

    Cerroni L, Barnhill R, Elder D. Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am J Surg Pathol 2010;34:314-326.

    • Search Google Scholar
    • Export Citation
  • 26

    Casper DJ, Ross KI, Messina JL. Use of anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma. Am J Dermatopathol 2010;32:650-654.

    • Search Google Scholar
    • Export Citation
  • 27

    Kapur P, Selim MA, Roy LC. Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis. Mod Pathol 2005;18:197-204.

    • Search Google Scholar
    • Export Citation
  • 28

    Vollmer RT. Use of Bayes rule and MIB-1 proliferation index to discriminate Spitz nevus from malignant melanoma. Am J Clin Pathol 2004;122:499-505.

    • Search Google Scholar
    • Export Citation
  • 29

    Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol 2008;30:117-122.

    • Search Google Scholar
    • Export Citation
  • 30

    Al Dhaybi R, Agoumi M, Gagne I. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi. J Am Acad Dermatol 2011;65:357-363.

    • Search Google Scholar
    • Export Citation
  • 31

    Zedek DC, McCalmont TH. Spitz nevi, atypical spitzoid neoplasms, and spitzoid melanoma. Clin Lab Med 2011;31:311-320.

  • 32

    Zembowicz A, Yang SE, Kafanas A, Lyle SR. Correlation between histologic assessment and fluorescence in situ hybridization using MelanoSITE in evaluation of histologically ambiguous melanocytic lesions. Arch Pathol Lab Med 2012;136:1571-1579.

    • Search Google Scholar
    • Export Citation
  • 33

    Zimmermann AK, Hirschmann A, Pfeiffer D. FISH analysis for diagnostic evaluation of challenging melanocytic lesions. Histol Histopathol 2010;25:1139-1147.

    • Search Google Scholar
    • Export Citation
  • 34

    Gerami P, Zembowicz A. Update on fluorescence in situ hybridization in melanoma: state of the art. Arch Pathol Lab Med 2011;135:830-837.

  • 35

    Gerami P, Jewell SS, Morrison LE. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol 2009;33:1146-1156.

    • Search Google Scholar
    • Export Citation
  • 36

    Morey AL, Murali R, McCarthy SW. Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation. Pathology 2009;41:383-387.

    • Search Google Scholar
    • Export Citation
  • 37

    Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003;163:1765-1770.

  • 38

    Harvell JD, Kohler S, Zhu S. High-resolution array-based comparative genomic hybridization for distinguishing paraffin-embedded Spitz nevi and melanomas. Diagn Mol Pathol 2004;13:22-25.

    • Search Google Scholar
    • Export Citation
  • 39

    Ali L, Helm T, Cheney R. Correlating array comparative genomic hybridization findings with histology and outcome in spitzoid melanocytic neoplasms. Int J Clin Exp Pathol 2010;3:593-599.

    • Search Google Scholar
    • Export Citation
  • 40

    Vanison C, Tanna N, Murthy AS. Comparative genomic hybridization for the diagnosis of melanoma. Eur J Plast Surg 2010;33:45-48.

  • 41

    Braun RP, Gutkowicz-Krusin D, Rabinovitz H. Agreement of dermatopathologists in the evaluation of clinically difficult melanocytic lesions: how golden is the 'gold standard'? Dermatology 2012;224:51-58.

    • Search Google Scholar
    • Export Citation
  • 42

    Wong JY, Sondak VK. Unanswered questions about margin recommendations for primary cutaneous melanoma. J Natl Compr Canc Netw 2012;10:357-365.

    • Search Google Scholar
    • Export Citation
  • 43

    Coit DG, Andtbacka R, Bichakjian CK. Melanoma. J Natl Compr Canc Netw 2009;7:250-275.

  • 44

    Kell MR, Ridge JA, Joseph N, Sigurdson ER. PET CT imaging in patients undergoing sentinel node biopsy for melanoma. Eur J Surg Oncol 2007;33:911-913.

    • Search Google Scholar
    • Export Citation
  • 45

    Schmid-Wendtner MH, Paerschke G, Baumert J. Value of ultrasonography compared with physical examination for the detection of locoregional metastases in patients with cutaneous melanoma. Melanoma Res 2003;13:183-188.

    • Search Google Scholar
    • Export Citation
  • 46

    Voit CA, van Akkooi AC, Schafer-Hesterberg G. Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma? J Clin Oncol 2009;27:4994-5000.

    • Search Google Scholar
    • Export Citation
  • 47

    Pearce MS, Salotti JA, Little MP. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 2012;380:499-505.

    • Search Google Scholar
    • Export Citation
  • 48

    Han D, Zager JS, Han G. The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol 2012;19:3888-3895.

  • 49

    Mills OL, Marzban S, Zager JS. Sentinel node biopsy in atypical melanocytic neoplasms in childhood: a single institution experience in 24 patients. J Cutan Pathol 2012;39:331-336.

    • Search Google Scholar
    • Export Citation
  • 50

    Howman-Giles R, Shaw HM, Scolyer RA. Sentinel lymph node biopsy in pediatric and adolescent cutaneous melanoma patients. Ann Surg Oncol 2010;17:138-143.

    • Search Google Scholar
    • Export Citation
  • 51

    Mu E, Lange JR, Strouse JJ. Comparison of the use and results of sentinel lymph node biopsy in children and young adults with melanoma. Cancer 2012;118:2700-2707.

    • Search Google Scholar
    • Export Citation
  • 52

    Roaten JB, Partrick DA, Pearlman N. Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents. J Pediatr Surg 2005;40:232-235.

    • Search Google Scholar
    • Export Citation
  • 53

    Berk DR, LaBuz E, Dadras SS. Melanoma and melanocytic tumors of uncertain malignant potential in children, adolescents and young adults—the Stanford experience 1995-2008. Pediatr Dermatol 2010;27:244-254.

    • Search Google Scholar
    • Export Citation
  • 54

    Cerrato F, Wallins JS, Webb ML. Outcomes in pediatric atypical spitz tumors treated without sentinel lymph node biopsy. Pediatr Dermatol 2012;29:448-453.

    • Search Google Scholar
    • Export Citation
  • 55

    Aldrink JH, Selim MA, Diesen DL. Pediatric melanoma: a single-institution experience of 150 patients. J Pediatr Surg 2009;44:1514-1521.

  • 56

    Hung T, Piris A, Lobo A. Sentinel lymph node metastasis is not predictive of poor outcome in patients with problematic spitzoid melanocytic tumors. Hum Pathol 2013;44:87-94.

    • Search Google Scholar
    • Export Citation
  • 57

    Wong SL, Balch CM, Hurley P. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol 2012;30:2912-2918.

    • Search Google Scholar
    • Export Citation
  • 58

    Faries MB, Thompson JF, Cochran A. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol 2010;17:3324-3329.

    • Search Google Scholar
    • Export Citation
  • 59

    Wong SL, Morton DL, Thompson JF. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol 2006;13:809-816.

    • Search Google Scholar
    • Export Citation
  • 60

    Kirkwood JM, Strawderman MH, Ernstoff MS. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.

    • Search Google Scholar
    • Export Citation
  • 61

    Kirkwood JM, Manola J, Ibrahim J. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670-1677.

    • Search Google Scholar
    • Export Citation
  • 62

    Kirkwood JM, Ibrahim J, Lawson DH. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the multicenter Eastern Cooperative Oncology Group phase II trial E2696. J Clin Oncol 2001;19:1430-1436.

    • Search Google Scholar
    • Export Citation
  • 63

    Kirkwood JM, Ibrahim JG, Sondak VK. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-2458.

    • Search Google Scholar
    • Export Citation
  • 64

    Kirkwood JM, Ibrahim JG, Sosman JA. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-2380.

    • Search Google Scholar
    • Export Citation
  • 65

    Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010;102:493-501.

    • Search Google Scholar
    • Export Citation
  • 66

    Navid F, Furman WL, Fleming M. The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma. Cancer 2005;103:780-787.

  • 67

    Gibbs P, Moore A, Robinson W. Pediatric melanoma: are recent advances in the management of adult melanoma relevant to the pediatric population. J Pediatr Hematol Oncol 2000;22:428-432.

    • Search Google Scholar
    • Export Citation
  • 68

    Eggermont AM, Suciu S, Santinami M. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372:117-126.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 216 175 1
PDF Downloads 18 15 1
EPUB Downloads 0 0 0